SCHEDULE 14A INFORMATION

(RULE 14a-101)

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934

Filed by the Registrant þ

Filed by a Party other than the Registrant o

Check the appropriate box:

o		Preliminary Proxy Statement
o		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ		Definitive Proxy Statement
o		Definitive Additional Materials
o		Soliciting Material Pursuant to sec.240.14a-12

SANTARUS, INC.

Payment of Filing Fee (Check the appropriate box):

þ		No fee required.
o		Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

	(1)		Title of each class of securities to which transaction applies:
	(2)		Aggregate number of securities to which transaction applies:
	(3)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)		Proposed maximum aggregate value of transaction:
	(5)		Total fee paid:

o		Fee paid previously with preliminary materials.
o		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)		Amount Previously Paid:
	(2)		Form, Schedule or Registration Statement No.:
	(3)		Filing Party:
	(4)		Date Filed:

SANTARUS, INC.
3721 Valley Centre Drive, Suite 400
San Diego, California 92130

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

     The Annual Meeting of the Stockholders of Santarus, Inc. will be held on June 12, 2008 at 1:00 p.m. at the Doubletree Hotel, 11915 El Camino Real, San Diego, California 92130, for the following purposes:

	•		elect two directors of Santarus;
	•		ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2008; and
	•		transact such other business as may be properly brought before the meeting or any adjournment thereof.

     Stockholders of record at the close of business on April 15, 2008 are entitled to notice of and to vote at our Annual Meeting and at any adjournment or postponement thereof.

     Accompanying this Notice is a proxy card. Whether or not you expect to be at our Annual Meeting, please complete, sign and date the enclosed proxy card and return it promptly. If you plan to attend our Annual Meeting and wish to vote your shares personally, you may do so at any time before the proxy is voted.

     All stockholders are cordially invited to attend the meeting.

By Order of the Board of Directors,

Gerald T. Proehl
President, Chief Executive Officer and Director

San Diego, California
April 25, 2008

SANTARUS, INC.

PROXY STATEMENT

     The board of directors of Santarus, Inc., a Delaware corporation (“Santarus,” the “company,” “we” or “us”), is soliciting the enclosed proxy card for use at our Annual Meeting of Stockholders to be held on June 12, 2008 at 1:00 p.m. at the Doubletree Hotel, 11915 El Camino Real, San Diego, California 92130, and at any adjournments or postponements thereof. This Proxy Statement will be first sent to stockholders on or about April 25, 2008.

     All stockholders who find it convenient to do so are cordially invited to attend the meeting in person. In any event, please complete, sign, date and return the proxy card in the enclosed envelope.

     A proxy may be revoked by written notice to our corporate secretary at any time prior to the voting of the proxy, or by executing a later proxy or by attending the meeting and voting in person. Unrevoked proxies will be voted in accordance with the instructions indicated in the proxies, or if there are no such instructions, such proxies will be voted (1) for the election of our board of directors’ nominees for director, and (2) for the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2008. Shares represented by proxies that reflect abstentions or include “broker non-votes” will be treated as present and entitled to vote for purposes of determining the presence of a quorum. Abstentions and “broker non-votes” will not be considered in determining whether director nominees have received the requisite number of affirmative votes. For ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year 2008, abstentions will have the effect of a vote “against” such proposal, and “broker non-votes,” although counted for purposes of determining the presence of a quorum, will have the effect of a vote neither “for” nor “against” such proposal.

     Stockholders of record at the close of business on April 15, 2008 (the “Record Date”) will be entitled to vote at the meeting or vote by proxy using the proxy card. As of that date, 51,316,931 shares of our common stock, par value $0.0001 per share, were outstanding. Each share of our common stock is entitled to one vote. A majority of the outstanding shares of our common stock entitled to vote, represented in person or by proxy at our Annual Meeting, constitutes a quorum. A plurality of the votes of the shares present in person or represented by proxy at our Annual Meeting and entitled to vote on the election of directors is required to elect directors; and a majority of the shares present in person or represented by proxy and entitled to vote thereon is required for the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2008.

     The cost of preparing, assembling and mailing the Notice of Annual Meeting, Proxy Statement and proxy card will be borne by us. In addition to soliciting proxies by mail, our officers, directors and other regular employees, without additional compensation, may solicit proxies personally or by other appropriate means. It is anticipated that banks, brokers, fiduciaries, other custodians and nominees will forward proxy soliciting materials to their principals, and that we will reimburse such persons’ out-of-pocket expenses.

PROPOSAL 1

ELECTION OF DIRECTORS

     Our board of directors currently consists of seven members. Our Amended and Restated Certificate of Incorporation provides for the classification of our board of directors into three classes, as nearly equal in number as possible, with staggered terms of office and provides that upon the expiration of the term of office for a class of directors, nominees for such class shall be elected for a term of three years or until their successors are duly elected and qualified. At this meeting, two nominees for director are to be elected as Class II directors for a three-year term expiring at our 2011 annual meeting of stockholders. The nominees are Michael E. Herman and Kent Snyder. The Class I and Class III directors have two years and one year, respectively, remaining on their terms of office.

     A plurality of the votes of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on the election of directors is required to elect directors. If no contrary indication is made, proxies in the accompanying form are to be voted for our board of directors’ nominees or, in the event any of such nominees is not a candidate or is unable to serve as a director at the time of the election (which is not currently expected), for any nominee who shall be designated by our board of directors to fill such vacancy.

Information Regarding Directors

     The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for director:

Nominees for Election for a Three-Year Term Expiring at the
2011 Annual Meeting of Stockholders

Name		Age				Present Position with the Company
Michael E. Herman			66			Director
Kent Snyder			54			Director

     Michael E. Herman has served as a member of our board of directors since September 2003. From January 1992 to December 2000, Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999, he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990, Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a director of Senomyx, Inc., a biotechnology company, Cerner Corporation, a health care information technology company, and also is a Trustee of Rensselaer Polytechnic Institute and the University of Chicago Graduate School of Business. Mr. Herman also previously served as a director of Janus Capital, Eloquent, Inc. and Agouron Pharmaceuticals, Inc. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.

     Kent Snyder has served as a member of our board of directors since September 2004. Since June 2003, Mr. Snyder has been the President and Chief Executive Officer and a director of Senomyx, Inc., a San Diego-based biotechnology company. Prior to joining Senomyx, from October 2001 to June 2003, Mr. Snyder was retired. From July 1991 to October 2001, Mr. Snyder held various management positions with Agouron Pharmaceuticals, Inc., a Pfizer company, including President of Global Commercial Operations. Prior to holding the position of President of Global Commercial Operations, Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder holds a B.S. from the University of Kansas and an M.B.A. from Rockhurst College.

Members of the Board of Directors Continuing in Office

Term Expiring at the
2009 Annual Meeting of Stockholders

Name		Age				Present Position with the Company
Gerald T. Proehl			49			President, Chief Executive Officer and Director
David F. Hale			59			Chairman of the Board
Ted W. Love, M.D.			49			Director

     Gerald T. Proehl has served as our President and Chief Executive Officer and as a director since January 2002. From March 2000 through December 2001, Mr. Proehl was our President and Chief Operating Officer. From April 1999 to March 2000, Mr. Proehl was our Vice President, Marketing and Business Development. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years, where he served in various capacities in multiple therapeutic areas including gastrointestinal, cardiovascular, wound care and central nervous system, and from March 1997 to April 1999 served as Vice President of Global Marketing. While at Hoechst Marion Roussel, Mr. Proehl oversaw the co-promotion of the proton pump inhibitor Prilosec^® by Hoechst Marion Roussel and Astra Merck Inc. and was responsible for the marketing of gastrointestinal products Carafate^® and Pentasa^®, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.

     David F. Hale has been Chairman since February 2004 and has served as a member of our board of directors since June 2000. Since January 2008, Mr. Hale has served as Interim Chief Executive Officer and Executive Chairman of the board of directors of Somaxon Pharmaceuticals, Inc. Prior to that time, Mr. Hale was a co-founder and served as Non-Executive Chairman of Somaxon’s board of directors since August 2003. Since May 2006, Mr. Hale has been Chairman and Chief Executive Officer of Hale BioPharma Ventures, LLC, which is focused on the formation and development of biotechnology and specialty pharmaceutical companies. From October 2000 to May 2006, Mr. Hale served as President and Chief Executive Officer of CancerVax Corporation, a biotechnology company focused on the development of products for the treatment and control of cancer. From December 2000 to May 2006, Mr. Hale was also a director of CancerVax. In May 2006, CancerVax merged with Micromet AG to form Micromet, Inc., a biopharmaceutical company, of which Mr. Hale is Chairman. Prior to joining CancerVax Corporation, Mr. Hale served as President and Chief Executive Officer and a director of Women First HealthCare, Inc., a specialty healthcare company, from January 1998 to May 2000. From June 1987 to October 1997, he served as President and Chief Executive Officer of Gensia Sicor Inc. (acquired by Teva Pharmaceutical Industries Limited), formerly Gensia Inc., a specialty pharmaceutical company, and was Chairman of the board of directors from May 1991 to February 1997. From February 1987 to September 1994, Mr. Hale served as Chairman of Viagene, Inc., a biotechnology company. He served as President and a director of Hybritech, Incorporated, a biotechnology company, from 1982 until May 1987. Mr. Hale has served as Chairman of the board of directors of Metabasis Therapeutics, Inc. since August 2006 and as a director since April 1997. Mr. Hale holds a B.A. in biology and chemistry from Jacksonville State University.

     Ted W. Love, M.D. has served as a member of our board of directors since March 2005. He was appointed President and Chief Executive Officer of Nuvelo, Inc., a biopharmaceutical company, in March 2001, having been appointed President and Chief Operating Officer of Nuvelo in January 2001. He has served as a director of that company since February 2001 and became Chairman of the board of directors in September 2005. He joined Nuvelo from Theravance, Inc., a biopharmaceutical company, where he served as Senior Vice President of Development from February 1998 to January 2001. Prior to that, he spent six years at Genentech, Inc., a biotechnology company, holding a number of senior management positions in medical affairs and product development. Dr. Love has served as a director of Affymax, Inc. since July 2006. He also serves on the 29-member California Independent Citizen’s Oversight Commission, which oversees the $3 billion allocated to stem cell research authorized by California Proposition 71. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

Term Expiring at the
2010 Annual Meeting of Stockholders

Name		Age				Present Position with the Company
Daniel D. Burgess			46			Director
Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.)			70			Director

     Daniel D. Burgess has served as a member of our board of directors since July 2004. Since May 2007, Mr. Burgess has been President and Chief Executive Officer as well as a director of Mpex Pharmaceuticals, Inc., a private biopharmaceutical company. From August 1999 to May 2007, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., a pharmaceutical company. Mr. Burgess joined Hollis-Eden from Nanogen Inc., a supplier of molecular diagnostic tests, where he served as Vice President and Chief Financial Officer. Prior to joining Nanogen in 1998, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited), formerly Gensia Inc., a specialty pharmaceutical company, and Gensia Automedics, Inc., a partially owned subsidiary of Gensia Sicor. He served as President and a director of Gensia Automedics, where he was responsible for all functional areas of this medical products company. In addition, he was Vice President and Chief Financial Officer of Gensia Sicor, where he was responsible

for finance, investor relations, business development and other administrative functions. Prior to joining Gensia, Mr. Burgess held positions at Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess has served as a director of Metabasis Therapeutics, Inc. since March 2004. He holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.

     Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.) has served as a member of our board of directors since February 2005. Dr. Carter has been a venture partner at S.V. Life Sciences Advisers LLP since 1998. He retired from Zeneca, PLC, a publicly-traded global pharmaceutical company, in 1998. Dr. Carter served Zeneca as International Medical Director from 1986 to 1989 and International Marketing Director from 1990 to 1995. From 1976 to 1984, Dr. Carter held several positions with Roche Products, Ltd., including head of Medical Development and Medical Affairs, and Director of the Pharmaceutical Division. Dr. Carter currently serves as a director of Micromet, Inc., a biopharmaceutical company, and GTx, Inc., a men’s health biotechnology company, in the U.S. He also serves on the boards of directors of European biopharmaceutical companies, Metris Therapeutics, Ltd., where he is Chairman of the board of directors, and Fulcrum Ltd. He is an elected fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a bachelor’s degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.).

Director Independence

     Messrs. Burgess, Hale, Herman, Snyder and Drs. Carter and Love are independent directors, as defined in the Nasdaq Stock Market qualification standards.

Board Meetings

     Our board of directors held 11 meetings, including telephonic meetings, during 2007. No director who served as a director during the past year attended fewer than 75% of the aggregate of the total number of meetings of our board of directors and the total number of meetings of committees of our board of directors on which he served.

Committees of the Board

     Audit Committee. Our audit committee currently consists of Messrs. Burgess, Hale and Snyder. The audit committee held seven meetings, including telephonic meetings, during 2007. All members of the audit committee are independent directors, as defined in the Nasdaq Stock Market qualification standards. Our board of directors has determined that each of Messrs. Burgess, Hale and Snyder qualifies as an “audit committee financial expert” as that term is defined in the rules and regulations established by the Securities and Exchange Commission. The audit committee is governed by a written charter approved by our board of directors, a copy of which is available on our web site at www.santarus.com. The functions of this committee include:

	•		meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting;
	•		meeting with our independent registered public accounting firm and with internal financial personnel regarding these matters;
	•		engaging our independent registered public accounting firm; and
	•		reviewing our audited financial statements and reports and discussing the statements and reports with our management and our independent registered public accounting firm, including any significant adjustments, management judgments and estimates, new accounting policies and disagreements with management, if any.

Both our independent registered public accounting firm and internal financial personnel regularly meet privately with our audit committee and have unrestricted access to this committee.

     Nominating/Corporate Governance Committee. Our nominating/corporate governance committee currently consists of Drs. Love and Carter and Mr. Herman. The nominating/corporate governance committee held one meeting, a telephonic meeting, during 2007. All members of the nominating/corporate governance committee are independent directors, as defined

in the Nasdaq Stock Market qualification standards. The nominating/corporate governance committee is governed by a written charter approved by our board of directors, a copy of which is available on our web site at www.santarus.com. The functions of this committee include:

	•		reviewing and recommending nominees for election as directors;
	•		assessing the performance of our board of directors; and
	•		reviewing our corporate governance guidelines and considering other issues relating to corporate governance.

     Compensation Committee. Our compensation committee currently consists of Messrs. Herman, Hale and Snyder. The compensation committee held seven meetings, including telephonic meetings, during 2007. All members of the compensation committee are independent directors, as defined in the Nasdaq Stock Market qualification standards. The compensation committee is governed by a written charter approved by our board of directors, a copy of which is available on our web site at www.santarus.com. The functions of this committee include:

	•		carrying out our board of directors’ responsibilities relating to compensation of our executive officers, including by designing (in consultation with management and the board of directors), approving and/or recommending to our board of directors for approval and evaluating our compensation plans, policies and programs;
	•		exercising authority under our employee benefit plans; and
	•		advising and consulting with our executive officers regarding other matters related to compensation of our employees.

     With regard to executive compensation, the compensation committee of our board of directors has the primary authority to determine compensation for our executive officers. In addition, the compensation committee, together with the remaining independent members of our board of directors, have authority to review our President and Chief Executive Officer’s individual performance and compensation, as well as to establish and determine achievement of our annual corporate goals. For more information about the compensation committee’s involvement with executive compensation matters, please see the discussion below under the heading “Compensation Discussion and Analysis.”

     The compensation committee also has the primary authority to review, at least annually, and recommend to the board of directors all compensation for our non-employee directors in connection with their service on our board of directors. To aid its review of non-employee director compensation, the compensation committee reviews third party survey data for peer group companies and utilizes the services of one or more independent compensation consulting and survey firms.

Compensation Committee Interlocks and Insider Participation

     Messrs. Herman, Hale and Snyder serve on the compensation committee of our board of directors. No member of the compensation committee was at any time during the 2007 fiscal year or at any other time an officer or employee of our company. None of our executive officers serve, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our compensation committee. None of our executive officers serve, or in the past year has served, as a member of the compensation committee of any entity that has one or more executives serving on our board of directors.

Director Nomination Process

     Director Qualifications

     In evaluating director nominees, the nominating/corporate governance committee considers, among other things, the following factors:

	•		personal and professional integrity, ethics and values;
	•		experience in corporate management, such as serving as an officer or former officer of a publicly held company;

	•		experience in our industry and/or with relevant social policy concerns;
	•		experience as a board member of another publicly held company;
	•		diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; and
	•		practical and mature business judgment.

     The nominating/corporate governance committee’s goal is to assemble a board of directors that brings to our company a variety of perspectives and skills derived from high quality business and professional experience.

     Other than the foregoing, there are no stated minimum criteria for director nominees, although the nominating/corporate governance committee may also consider such other facts as it may deem are in the best interests of our company and our stockholders. The nominating/corporate governance committee also believes it is appropriate for at least one, and, preferably, several, members of our board of directors to meet the criteria for an “audit committee financial expert” as defined by Securities and Exchange Commission rules, and that a majority of the members of our board of directors be independent as required under the Nasdaq Stock Market qualification standards. The nominating/corporate governance committee also believes it is appropriate for our chief executive officer to serve as a member of our board of directors.

     Identification and Evaluation of Nominees for Directors

     The nominating/corporate governance committee identifies nominees for director by first evaluating the current members of our board of directors willing to continue in service. Current members with qualifications and skills that are consistent with the nominating/corporate governance committee’s criteria for board of directors service and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of our board of directors with that of obtaining a new perspective.

     If any member of our board of directors does not wish to continue in service or if our board of directors decides not to re-nominate a member for re-election, the nominating/corporate governance committee identifies the desired skills and experience of a new nominee in light of the criteria above. The nominating/corporate governance committee generally polls our board of directors and members of management for their recommendations. The nominating/corporate governance committee may also review the composition and qualification of the boards of directors of our competitors, and may seek input from industry experts or analysts. The nominating/corporate governance committee reviews the qualifications, experience and background of the candidates. Final candidates are interviewed by the members of the nominating/corporate governance committee and by certain of our other independent directors and executive management. In making its determinations, the nominating/corporate governance committee evaluates each individual in the context of our board of directors as a whole, with the objective of assembling a group that can best perpetuate the success of our company and represent stockholder interests through the exercise of sound judgment. After review and deliberation of all feedback and data, the nominating/corporate governance committee makes its recommendation to our board of directors. To date, the nominating/corporate governance committee has not utilized third-party search firms to identify board of directors candidates. The nominating/corporate governance committee may in the future choose to do so in those situations where particular qualifications are required or where existing contacts are not sufficient to identify an appropriate candidate.

     The nominating/corporate governance committee plans to evaluate any nominees recommended by stockholders in the same manner as it evaluates other nominees. To date, we have not received director candidate recommendations from our stockholders. Any recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by board members, management or other parties are evaluated. We do not intend to treat stockholder recommendations in any manner different from other recommendations.

     Pursuant to our Amended and Restated Bylaws, stockholders wishing to suggest a candidate for director should write to our corporate secretary. In order to be considered, the recommendation for a candidate must include the following written information: (i) the stockholders’ name and contact information, as they appear on our books; (ii) the class and number of shares of our capital stock which are owned beneficially and of record by the stockholder; (iii) a representation that the stockholder is a holder of record of our capital stock and entitled to vote at such meeting and intends to appear in person or

by proxy at the meeting to propose such nomination; (iv) a representation whether the stockholder intends or is part of a group which intends (y) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee and/or (z) otherwise to solicit proxies from stockholders in support of the nomination; (v) all information relating to such candidate that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A and Rule 14a-101 under the Securities Exchange Act of 1934, as amended (including such candidate’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected). In order to give the nominating/corporate governance committee sufficient time to evaluate a recommended candidate and/or include the candidate in our proxy statement for the 2009 annual meeting, the recommendation should be received by our corporate secretary at our principal executive offices pursuant to our procedures detailed in the section below entitled “Stockholder Proposals.”

Communications with our Board of Directors

     Our stockholders may contact our board of directors or a specified individual director by writing to our corporate secretary at Santarus, Inc., 3721 Valley Centre Drive, Suite 400, San Diego, California 92130. Our corporate secretary will relay all such communications to our board of directors, or individual members, as appropriate.

Code of Ethics

     Our company has established a Code of Business Conduct and Ethics that applies to our officers, directors and employees. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics, and is intended to qualify as a “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. Our company has established an Ethics Helpline at 1-800-869-9522 that is designed to receive anonymous reports of any known or suspected violations of our Code of Business Conduct and Ethics, Comprehensive Compliance Program for Sales and Marketing Activities or other applicable laws, rules and regulations.

Corporate Governance Documents

     Our company’s Code of Business Conduct and Ethics, Corporate Governance Guidelines, Audit Committee Charter, Compensation Committee Charter and Nominating/Corporate Governance Committee Charter are available, free of charge, on our web site at www.santarus.com. Please note, however, that the information contained on the web site is not incorporated by reference in, or considered part of, this Proxy Statement. We will also provide copies of these documents, free of charge, to any stockholder upon written request to Investor Relations, Santarus, Inc., 3721 Valley Centre Drive, Suite 400, San Diego, California 92130.

Report of the Audit Committee

     The audit committee oversees the company’s financial reporting process on behalf of the board of directors. Management has the primary responsibility for the financial statements and the reporting process including the systems of internal controls. In fulfilling its oversight responsibilities, the audit committee reviewed the audited financial statements in the company’s annual report with management, including a discussion of any significant changes in the selection or application of accounting principles, the reasonableness of significant judgments, the clarity of disclosures in the financial statements and the effect of any new accounting initiatives.

     The audit committee reviewed with Ernst & Young LLP, who are responsible for expressing an opinion on the conformity of the company’s audited financial statements with generally accepted accounting principles, their judgments as to the quality and acceptability of the company’s accounting principles and such other matters as are required to be discussed with the audit committee under generally accepted auditing standards, including the Statement on Auditing Standards No. 61 (Communication with Audit Committees), as currently in effect. In addition, the audit committee has discussed with Ernst & Young LLP their independence from management, and the company has received from Ernst & Young LLP the written disclosures and the letter required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees) and considered the compatibility of non-audit services with the auditors’ independence.

     The audit committee met with Ernst & Young LLP to discuss the overall scope of their services, the results of their audit and reviews, their evaluation of the company’s internal controls and the overall quality of the company’s financial reporting.

Ernst & Young LLP, as the company’s independent registered public accounting firm, also periodically updates the audit committee about new accounting developments and their potential impact on the company’s reporting. During the audit committee’s meetings with Ernst & Young LLP, the audit committee met with Ernst & Young LLP with and without management present. The audit committee is not employed by the company, nor does it provide any expert assurance or professional certification regarding the company’s financial statements. The audit committee relies, without independent verification, on the accuracy and integrity of the information provided, and representations made, by management and the company’s independent registered public accounting firm.

     In reliance on the reviews and discussions referred to above, the audit committee recommended to the company’s board of directors that the audited financial statements be included in the company’s annual report for the year ended December 31, 2007. The audit committee and the company’s board of directors also have recommended, subject to stockholder approval, the ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for 2008.

     This report of the audit committee shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the company specifically incorporates this information by reference, and shall not otherwise be deemed filed under such acts.

     The foregoing report has been furnished by the audit committee.

Daniel D. Burgess, Chairman
David F. Hale
Kent Snyder

Compensation of Directors

     Non-employee members of our board of directors receive a combination of cash compensation, in the form of annual retainers and meeting stipends, and equity incentive compensation, in the form of stock option awards, for their service on our board of directors. Any board member who is also an employee of our company does not receive separate compensation for service on our board of directors.

     Cash Compensation

          2007 Fiscal Year

     For the 2007 fiscal year, each non-employee director received an annual cash retainer of $25,000. The chairman of our board received an additional annual retainer of $30,000 and the chairs of the following board committees received the following additional annual retainers: (i) audit committee, $10,000; (ii) compensation committee, $5,000; and (iii) nominating/corporate governance committee, $2,500.

     Each non-employee director also received the following cash meeting stipends for each board and committee meeting attended: (i) $2,000 for each board meeting attended in-person and $1,000 for each board meeting attended by telephone; and (ii) $1,000 for each committee meeting attended in-person or by telephone.

     In addition, non-employee directors also received reimbursement of their reasonable out-of-pocket expenses in connection with attendance at board and committee meetings.

     Additional information about the cash compensation paid to our non-employee directors during the 2007 fiscal year is reflected in the table captioned “Director Compensation Table,” set forth below.

          2008 Fiscal Year

     The cash compensation program for our non-employee directors for the 2008 fiscal year is the same as described for the 2007 fiscal year.

     Equity Incentive Compensation

     Our non-employee directors also receive equity incentive compensation in connection with their service on our board of directors.

          2007 Fiscal Year

     For the 2007 fiscal year, on June 14, 2007, the date of the annual meeting of our stockholders, (i) each continuing non-employee director received an option to purchase 32,000 shares of common stock, (ii) the chairman of the board of directors received an additional annual option to purchase 10,000 shares of common stock, (iii) the chairman of our audit committee received an additional annual option to purchase 5,000 shares of common stock, (iv) the chairman of our compensation committee received an additional annual option to purchase 5,000 shares of common stock and (v) the chairman of our nominating/corporate governance committee received an additional annual option to purchase 2,500 shares of common stock. In addition, our policy provides that each non-employee director who is initially elected to our board of directors is granted an option to purchase 35,000 shares of our common stock in connection with his or her initial election to our board of directors. There were no non-employee directors initially elected to our board of directors in the 2007 fiscal year.

     These options have an exercise price per share equal to 100% of the fair market value of the underlying stock at the time of grant. The initial options granted to non-employee directors described above vest in three equal annual installments on each yearly anniversary of the date of grant, subject to the director’s continuing service on our board of directors on such dates. The annual options granted to non-employee directors described above vest in twelve equal monthly installments on each monthly anniversary of the date of grant, subject to the director’s continuing service on our board of directors on such dates. To the extent vested as of a non-employee director’s termination of membership on our board of directors, each such option granted on or after February 10, 2006 is exercisable for 12 months following such director’s termination of membership on our board of directors. The term of each option granted to a non-employee director is ten years. Upon a change of control (as defined in our amended and restated 2004 equity incentive award plan and our 1998 stock option plan), each option granted to a non-employee director becomes 100% vested in accordance with the terms of such plans.

     Additional information about stock option awards granted during the 2007 fiscal year to our non-employee directors is reflected in the table captioned “Director Compensation Table,” set forth below.

          2008 Fiscal Year

     The equity incentive compensation program for our non-employee directors for the 2008 fiscal year is the same as described for the 2007 fiscal year.

DIRECTOR COMPENSATION TABLE

     The table below summarizes the compensation paid by our company to non-employee directors for the fiscal year ended December 31, 2007.

		Fees Earned or				Option				All Other
		Paid in Cash				Awards				Compensation				Total
Name(1)`		($)				($)(2)				($)				($)
David F. Hale		$	79,000			$	136,179			$	—			$	215,179
Daniel D. Burgess			57,000				134,723				—				191,723
Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.)			40,000				125,661				—				165,661
Michael E. Herman			54,000				124,496				—				178,496
Ted W. Love, M.D.			43,500				129,531				—				173,031
Kent Snyder			53,000				121,545				—				174,545

Director Attendance at Annual Meetings

     Although our company does not have a formal policy regarding attendance by members of our board of directors at our Annual Meeting, we encourage all of our directors to attend. Five of our seven then current directors attended our 2007 annual meeting of stockholders.

     Our board of directors unanimously recommends a vote “FOR” each nominee listed above. Proxies solicited by our board of directors will be so voted unless stockholders specify otherwise on the accompanying proxy card.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

     The following table sets forth information regarding the beneficial ownership of our common stock as of March 31, 2008 for:

	•		each of our Named Executive Officers (as defined below in “Executive Compensation and Other Information – Summary Compensation Table”);
	•		each of our directors;
	•		each person known by us to beneficially own more than 5% of our common stock; and
	•		all of our executive officers and directors as a group.

     Information with respect to beneficial ownership has been furnished by each executive officer, director, or beneficial owner of more than 5% of our common stock. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to the securities. Except as indicated by footnote, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. The number of shares of common stock used to calculate the percentage ownership of each listed person includes the shares of common stock underlying options or warrants held by such persons that are exercisable as of May 30, 2008, which is 60 days after March 31, 2008.

     Percentage of beneficial ownership is based on 51,316,931 shares of common stock outstanding as of March 31, 2008.

     Unless otherwise indicated, the address for the following stockholders is c/o Santarus, Inc., 3721 Valley Centre Drive, Suite 400, San Diego, CA 92130.

		Shares				Percent
		Beneficially				Beneficially
Name and Address of Beneficial Owner		Owned				Owned
Named Executive Officers and Directors:
Gerald T. Proehl(1)			1,113,875				2.1	%
Debra P. Crawford(2)			359,909				*
Julie A. DeMeules(3)			209,581				*
William C. Denby, III(4)			299,189				*
Warren E. Hall(5)			362,996				*
David F. Hale(6)			320,952				*
Daniel D. Burgess(7)			132,000				*
Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.)(8)			112,000				*
Michael E. Herman(9)			235,970				*
Ted W. Love, M.D.(10)			117,000				*
Kent Snyder(11)			113,000				*
5% Stockholders:
Westfield Capital Management Co. LLC(12)			8,355,816				16.3
Funds affiliated with Split Rock Partners, LLC(13)			4,385,090				8.5
Funds affiliated with BlackRock, Inc.(14)			3,482,350				6.8
All directors and executive officers as a group (14 persons)(15)			3,817,704				7.0

EXECUTIVE COMPENSATION AND OTHER INFORMATION

Our Executive Officers and Senior Management

     The following table sets forth information as to persons who serve as our executive officers and senior management as of March 31, 2008.

Name		Age				Position
Gerald T. Proehl			49			President, Chief Executive Officer and Director
Debra P. Crawford			50			Senior Vice President, Chief Financial Officer, Treasurer and Secretary
Julie A. DeMeules			55			Senior Vice President, Human Resources
William C. Denby, III			52			Senior Vice President, Commercial Operations
Warren E. Hall			55			Senior Vice President, Manufacturing and Product Development
Michael D. Step			48			Senior Vice President, Corporate Development
E. David Ballard II, M.D.			52			Vice President, Clinical Research and Medical Affairs
Maria Bedoya-Toro, PhD.			56			Vice President, Regulatory Affairs and Quality Assurance
Carey J. Fox, J.D.			39			Vice President, General Counsel
Blake A. Boland			47			Vice President, Sales
Jonathan M. Hee			49			Vice President, Commercial Affairs
Martha L. Hough			54			Vice President, Finance and Investor Relations
Thomas J. Joyce			48			Vice President, Marketing and National Accounts

     Gerald T. Proehl has served as our President and Chief Executive Officer and as a director since January 2002. From March 2000 through December 2001, Mr. Proehl was our President and Chief Operating Officer. From April 1999 to March 2000, Mr. Proehl was our Vice President, Marketing and Business Development. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years, where he served in various capacities in multiple therapeutic areas including gastrointestinal, cardiovascular, wound care and central nervous system, and from March 1997 to April 1999 served as Vice President of Global Marketing. While at Hoechst Marion Roussel, Mr. Proehl oversaw the co-promotion of the proton pump inhibitor Prilosec^® by Hoechst Marion Roussel and Astra Merck Inc. and was responsible for the marketing of gastrointestinal products Carafate^® and Pentasa^®, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.

     Debra P. Crawford joined Santarus in November 2000 as Vice President, Chief Financial Officer, Treasurer and Secretary and was promoted to Senior Vice President, Chief Financial Officer, Treasurer and Secretary in December 2003. Prior to joining Santarus, Ms. Crawford served as Vice President, Chief Financial Officer and Treasurer from July 1998 to May 2000 for Women First HealthCare, Inc., a specialty healthcare company. Ms. Crawford was also Assistant Secretary of Women First from July 1998 to February 1999 and Secretary from March 1999 to May 2000. From May 2000 to October 2000 and from March 1997 to August 1998, Ms. Crawford was self-employed and provided financial consulting services in the area of corporate development and in the capacity of acting chief financial officer. Ms. Crawford also served as Chief Financial Officer, Vice President of Finance and Administration and Treasurer of IVAC Holdings, Inc. from January 1996 to December 1996 and of IVAC Medical Systems, Inc., a medical device company, from January 1995 to December 1996. From September 1981 to December 1994, Ms. Crawford served in various financial positions within companies of the medical device division of Eli Lilly & Company. Ms. Crawford is a certified public accountant and holds a B.S. in business administration from San Diego State University.

     Julie A. DeMeules joined Santarus in January 2004 as Vice President, Human Resources and was promoted to Senior Vice President, Human Resources in February 2006. From January 2000 to November 2003, Ms. DeMeules served as Vice President, Human Resources at Quidel Corporation, a manufacturer and distributor of medical diagnostic products. From February 1991 to January 2000, Ms. DeMeules was employed with Advanced Tissue Sciences, a biotechnology company, most recently serving as Vice President, Human Resources. Prior to joining Advanced Tissue Sciences, Ms. DeMeules served as Director of Human Resources at Square D Corporation, a provider of electrical products, from June 1990 to February 1991. Prior to joining Square D Corporation, Ms. DeMeules served for several years as Vice President of Human Resources of Signet Armorlite, Inc., a manufacturer and distributor of ophthalmic lenses and supplies. Ms. DeMeules holds a B.A. in business administration from the University of San Diego and an M.B.A. from San Diego State University.

     William C. Denby, III joined Santarus in February 2002 as Senior Vice President, Commercial Operations. Prior to joining Santarus, from October 2001 to February 2002, Mr. Denby served as Senior Vice President of Commercial Operations of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From June 1997 to October 2001, Mr. Denby served as Senior Vice President and Vice President of Sales and Marketing for Agouron. From January 1995 to June 1997, Mr. Denby served as Senior Director of Sales and Marketing and Senior Director, Commercial and Marketing Affairs for Agouron. Prior to that, Mr. Denby was at Marion Laboratories for 18 years, holding various positions in corporate finance, strategic planning, and sales and marketing. While at Marion Laboratories, Mr. Denby was responsible for promoting a diverse product line which included brands such as Cardizem^®, Nicorette^® and the duodenal ulcer drug Carafate, and he helped secure managed care formulary acceptance for these products. Mr. Denby holds a B.A. in English from the State University of New York at Fredonia and an M.B.A. from Rockhurst College.

     Warren E. Hall joined Santarus in July 2001 as Vice President, Manufacturing and Product Development and was promoted to Senior Vice President, Manufacturing and Product Development in December 2003. Prior to joining Santarus, Mr. Hall served as Senior Director of Development from July 2000 to July 2001 at Dura Pharmaceuticals, a specialty pharmaceutical company that was acquired by Elan Corporation, plc, a pharmaceutical company. Mr. Hall served as Senior Director of Program Management for the pulmonary group at Dura from February 1999 to July 2000, and as Senior Director of Manufacturing from July 1998 to February 1999. From November 1995 to June 1998, Mr. Hall served as Director of Manufacturing Operations at Cell Therapeutics, Inc., a cancer treatment company. Prior to Cell Therapeutics, Mr. Hall was with Mallinckrodt, Inc., a pharmaceutical and specialty chemical company, for 17 years, serving in various capacities, most recently as Director of Worldwide Manufacturing. Mr. Hall holds a B.A. in chemistry and biology from Greenville College and an M.S. in organic chemistry from Southern Illinois University.

     Michael D. Step joined Santarus as Senior Vice President, Corporate Development in February 2005. Prior to joining Santarus, he served from August 2000 to February 2005 with Amylin Pharmaceuticals, Inc., a biopharmaceutical company, most recently as Vice President, Corporate Development. In this capacity, he was responsible for leading corporate development activities, including product licensing, strategic planning, and mergers and acquisitions evaluations. Prior to Amylin, he was Senior Director, Business Development at Dura Pharmaceuticals, Inc., a pharmaceutical company, from May 1998 to July 2000. In this position, his duties included licensing of marketed pharmaceutical products. Prior to that, he served in corporate development and strategic planning at Hoffmann-La Roche and sales and management roles at Roche Labs and Syntex Labs. Mr. Step holds a B.A. in political science from Vanderbilt University and an M.B.A. from the University of Southern California.

     E. David Ballard II, M.D. joined Santarus in March 2004 as Vice President, Clinical Research, was appointed Vice President, Medical Affairs in September 2005 and was promoted to Vice President, Clinical Research and Medical Affairs in March 2006. From March 2000 to February 2004, Dr. Ballard served in various positions at TAP Pharmaceutical Products Inc., a pharmaceutical company, most recently serving as Therapeutic Area Head, Gastroenterology and Internal Medicine. From July 1997 to March 2000, Dr. Ballard was a Medical Director at Abbott Laboratories, a pharmaceutical company. Dr. Ballard holds a B.S. in biology from Morehouse College and an M.D. from the Medical College of Ohio. Dr. Ballard is also certified as a gastroenterologist by the American Board of Internal Medicine.

     Maria Bedoya-Toro, PhD joined Santarus in May 2007 as Vice President, Regulatory Affairs and Quality Assurance. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc. from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya-Toro worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006.

From 2000 to 2003 she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000 Dr. Bedoya-Toro worked at BASF Bioresearch Corporation as Director Regulatory Affairs/Quality, and from 1996 to 1998 she worked as Director Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996 Dr. Bedoya-Toro worked at Rhone-Poulenc Rorer in a number of positions of increasing responsibility in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya-Toro holds an M.B.A from the University of Chicago and a Ph.D. in bio-analytical chemistry from Ohio University. In addition she holds an M.A. in bio-analytical chemistry and a B.S. in chemistry from Western Michigan University.

     Carey J. Fox joined Santarus as Senior Director, Legal Affairs in March 2002, served as Vice President, Legal Affairs from May 2004 to February 2006 and was promoted to Vice President, General Counsel in March 2006. Prior to joining Santarus, Ms. Fox served as Director, Legal Affairs for Elan Pharmaceuticals, Inc., a pharmaceutical company, from January 2002 to March 2002. Prior to joining Elan, Ms. Fox was associated with the law firm of Brobeck, Phleger & Harrison LLP from May 1998 to December 2001 and with the law firm of Fennemore Craig from January 1996 to May 1998, where she represented a variety of clients in general corporate and securities law matters. Ms. Fox is a member of the State Bar of California and holds a B.A. in social ecology from the University of California, Irvine and a J.D. from Arizona State University.

     Blake A. Boland has served as Vice President, Sales since July 2004 and previously served as Director, National Sales beginning in January 2004. Prior to joining Santarus, Mr. Boland was with Aventis Pharmaceuticals, a global pharmaceutical company, for 16 years. From November 1998 to December 2003, Mr. Boland served as a Regional Sales Director, where he was responsible initially for building a new primary care sales organization in the western U.S. During his career with Aventis and predecessor companies, Mr. Boland held various positions in sales, marketing and sales management in such therapeutic areas as gastroenterology, cardiovascular, respiratory, diabetes and anti-infectives. Mr. Boland holds a B.A. in business administration from Graceland College and an M.B.A. from Rockhurst College.

     Jonathan M. Hee joined Santarus in January 2004 as Vice President, Commercial Affairs. From October 2000 to December 2003, Mr. Hee served as Vice President, Sales and Marketing Services at Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From October 1996 to October 2000, Mr. Hee served as Director and Senior Director, Sales and Marketing Services for Agouron. Mr. Hee was a Senior Manager of Segment Marketing for Agouron from November 1995 to October 1996. Prior to joining Agouron, Mr. Hee was with Gensia Inc., a cardiovascular and multi-source injectable drug company, where he held various management roles including Associate Director positions in marketing and market planning. Mr. Hee holds a B.S. in chemical engineering from Stanford University and an M.B.A. from Harvard University.

     Martha L. Hough joined Santarus in January 2005 as Vice President, Finance and Investor Relations. From August 2002 to December 2004, and September 1998 to October 1999, Ms. Hough was a self-employed consultant to medical technology and pharmaceutical companies. From November 1999 to July 2002, Ms. Hough was Vice President, Business Development, and Chief Financial Officer of LMA North America, Inc., a profitable private medical device company. From 1987 to 1998, Ms. Hough worked in various finance, investor relations, and marketing positions at Gensia Sicor, Inc., serving as Vice President, Finance and Corporate Communications there from January 1995 to June 1998. Ms. Hough holds a B.S. in psychology from Colorado State University and an M.B.A. from the Tuck School of Business at Dartmouth College.

     Thomas J. Joyce joined Santarus in January 2004 as Vice President, Marketing and National Accounts. From April 2002 to January 2004, Mr. Joyce served as Senior Director, Marketing at Neurocrine Biosciences, Inc., a drug discovery and development company. From July 1999 to March 2002, Mr. Joyce served as Senior Director, Global Marketing Planning of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From September 1997 to June 1999 and from May 1996 to August 1997, Mr. Joyce served as Associate Director of Corporate Development and Senior Market Manager, respectively, of Agouron. Prior to joining Agouron, Mr. Joyce held various sales and sales management positions at Hoechst Marion Roussel. Mr. Joyce holds a B.A. in psychology from the University of Dayton.

Compensation Discussion and Analysis

     Executive Compensation Program Overview

     Our compensation programs for our executive officers and other employees are designed to:

	•		attract and retain highly skilled individuals by establishing salaries, benefits, and incentive compensation which are competitive with similar positions in other companies with whom we compete for employees and which are internally equitable within our company;
	•		closely align compensation for our employees with the company’s performance on both a short-term and long-term basis;
	•		reward and provide differentiated compensation based on individual performance; and
	•		further enhance our employees’ long-term incentive to increase stockholder value and the company’s stock price by providing a portion of our total compensation in the form of company equity, through stock options and stock ownership.

     To accomplish those goals, compensation for our employees, including our executive officers, generally consists of the following elements: (1) base salary, (2) annual cash bonuses, (3) long-term incentives through stock option awards and stock ownership and (4) other welfare and retirement savings benefits. In addition, our executive officers are entitled to potential payments upon specified termination or change in control events.

     The compensation committee of our board of directors has the primary authority to determine compensation for the company’s executive officers. In addition, the compensation committee, together with the remaining independent members of our board of directors, have authority to review our President and Chief Executive Officer’s individual performance and compensation, as well as to establish and determine achievement of our annual corporate goals. Each year, our compensation committee and the remaining independent members of our board of directors review the compensation of Gerald T. Proehl, our President and Chief Executive Officer, as well as his individual performance for the calendar year under review and our company’s overall performance. The compensation committee also reviews compensation for the other executive officers on an annual basis and his or her individual performance for the calendar year under review. To aid the compensation committee’s review, Mr. Proehl provides a recommendation concerning compensation and performance for each executive officer, excluding himself. The annual review of compensation for our executive officers and Mr. Proehl for the 2007 fiscal year took place at scheduled compensation committee and board meetings in February 2007, and the determination of bonuses earned for performance during the 2007 fiscal year took place at our scheduled board meeting in February 2008.

     The compensation committee’s overall objective, or compensation philosophy, when establishing levels of compensation for a particular executive officer for the 2007 fiscal year was to target total cash compensation at the 50^th percentile level and equity compensation at the 75^th percentile, when compared to comparable positions within other comparable specialty pharmaceutical companies, or peer companies. The compensation committee has established this philosophy to emphasize variable and performance-based compensation over fixed compensation, to better manage cash burn and to align the long-term goals of executives and stockholders towards growth in stock price. To ensure that the compensation committee’s executive compensation decisions for the 2007 fiscal year were consistent with this philosophy, the committee established the following list of peer companies, which companies were comparable at the time the list was established in 2006 to our company in various regards, including the nature of operations, stage of development, market capitalization and/or number of employees:

	•		Auxilium Pharmaceuticals, Inc.
	•		Avanir Pharmaceuticals
	•		Axcan Pharma Inc.
	•		BioMarin Pharmaceutical Inc.
	•		Connetics Corporation
	•		CV Therapeutics, Inc.
	•		Depomed, Inc.
	•		Enzon Pharmaceuticals, Inc.

	•		GTx, Inc.
	•		Incyte Corporation
	•		InterMune, Inc.
	•		LifeCell Corporation
	•		Ligand Pharmaceuticals Inc.
	•		Neurocrine Biosciences, Inc.
	•		NitroMed, Inc.
	•		Noven Pharmaceuticals, Inc.

	•		Pain Therapeutics, Inc.
	•		Pharmion Corp.
	•		Pozen Inc.
	•		Salix Pharmaceuticals, Ltd.
	•		Sciele Pharma, Inc.
	•		Somaxon Pharmaceuticals, Inc.
	•		The Medicines Company
	•		ViroPharma Incorporated

     To assist with the analysis of executive compensation for the 2007 fiscal year, the compensation committee engaged Radford Surveys and Consulting, or Radford, to provide compensation consulting services. Radford reports directly to the compensation committee, and the committee has the sole authority to hire, fire and direct the work of Radford as its advisor. The compensation committee requested Radford to advise it on a variety of compensation-related issues, including:

	•		providing general information concerning executive compensation trends and developments,
	•		compiling, analyzing and presenting third party survey data, and
	•		assessing various forms of equity compensation.

The compensation committee believes that Radford is able to provide independent, objective compensation advice to the compensation committee. Other than providing the advice and services described above, Radford provided no other services to either the company or the compensation committee during the 2007 fiscal year.

     The third party survey data presented by Radford was designed to ensure that the executive compensation decisions were consistent with the overall compensation philosophy and included survey data relating to levels of base salaries, incentive cash bonuses and equity awards from the Radford Biotech Survey for executive positions within the 24 peer companies described above. When reviewing the third party survey data, the compensation committee considered whether the total cash and equity compensation for our executive officers was generally at the 50^th and 75^th percentiles, respectively, when compared to compensation paid to executives holding comparable positions within our peer companies. The compensation committee compared the executive compensation programs as a whole and also compared the pay of individual executives if the jobs were sufficiently similar to make the comparisons meaningful.

     The compensation committee also utilized “tally sheets,” prepared with the assistance of management, when making its executive compensation decisions for the 2007 fiscal year. The “tally sheets” described the nature and/or value of each element of compensation payable to each executive officer, and enabled the compensation committee to evaluate each compensation element in the context of the executive’s overall total compensation. The specific information set forth in the “tally sheets” was similar to the information set forth in the tables following this “Compensation Discussion and Analysis” section and included the following information relating to the 2007 fiscal year: a summary description of total compensation, a description of options granted and outstanding and a description of potential payments upon termination or change in control.

     Elements of the Executive Compensation Program

          Base Salary

     As a general matter, the base salary for each executive is initially established and approved by the compensation committee at the time the officer is hired, taking into account the officer’s qualifications, experience, role and responsibilities, prior salary and competitive salary information. Under the terms of our executive officer employment agreements, each officer is entitled to an annual review of his or her base salary, in the sole discretion of the compensation committee. Any year-to-year adjustments to each executive officer’s base salary are determined by an assessment by the compensation committee (with assistance from management as described above and with the involvement of the independent members of our board of directors, with respect to Mr. Proehl) of her or his individual performance (including the executive’s accomplishments and effectiveness), overall company performance, the company’s budget for merit increases and competitive salary information. In assessing competitive salary information, the compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) review and consider independent third party data related to salary levels for similar executive positions in our peer companies, as described above.

     In connection with the annual review of his performance at the scheduled compensation committee and board of directors meetings in February 2007, Mr. Proehl received a 5% merit increase and a 9.4% market adjustment to his level of base salary, which was effective in March 2007 and resulted in an increase in Mr. Proehl’s base salary from $437,000 to $500,000. At this same time, the other Named Executive Officers each received a merit increase in his or her level of base salary ranging from 3% to 5%, effective in March 2007. In addition, Ms. DeMeules received a 6.1% market adjustment to her level of base salary, effective in March 2007.

     In determining these adjustments, the compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) considered each executive officer’s individual performance, the company’s overall performance and competitive salary information, based on the third party survey data compiled by Radford. As described above, when reviewing the third party survey data, the compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) considered whether total cash compensation for our executive officers was generally at the 50^th percentile of the total compensation paid to executives holding comparable positions within our peer companies. Consistent with the overall compensation philosophy, the total cash compensation for our executive officers, including the base salary levels described above and the cash bonuses described below, was at less than the 50th percentile of the total cash compensation paid to executives holding comparable positions within our peer companies, due to the fact that our executive officers received less than 100% of their target cash bonuses based on company performance consistent with the pay for performance nature of the bonus plan.

          Annual Cash Bonuses

     Our executive officers, as well as all of our other employees (with the exception of our field-based commercial employees), were eligible to receive annual cash bonuses pursuant to our 2007 bonus plan.

     Payments for executive officers under our 2007 bonus plan were based 100% on achieving established corporate goals (rather than on achievement of individual goals) and were determined as a percentage of each executive officer’s base salary. We believe that by basing the potential bonus payments for executive officers solely on achievement of corporate goals, we ensure that each executive officer’s performance is fully aligned with the overall executive team and company objectives, as well as focused on increasing stockholder value by providing incentives for corporate performance. The performance goals are established each year so that in the board’s and committee’s determination they are not substantially certain to be attained absent strong performance by the executive officers and the company as a whole. The company’s historical level of attainment of the corporate goals for the last two years has been as follows: 2005 fiscal year (42.5%); and 2006 fiscal year (102%). These varying levels of attainment provide further insight concerning the level of performance required to fully achieve the corporate goals, and the likelihood of doing so, from year to year.

     Under the terms of our 2007 bonus plan, the target bonus for Mr. Proehl, our President and Chief Executive Officer, was 50% of base salary, and the target bonus for each of our other executive officers was 35% of base salary. The target bonus percentage amounts were established through an analysis that included a review of third party survey data for our peer companies. As described above, when reviewing the third party survey data, the compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) considered whether total cash compensation for our executive officers was generally at the 50^th percentile of the total compensation paid to executives holding comparable positions within our peer companies, in the case of the target bonuses, assuming the executive officers fully achieve the corporate performance goals established by our board. Each executive officer was then eligible to receive a bonus ranging from zero to 150% of his or her target bonus, based on the level of the company’s achievement of its corporate performance goals for the 2007 fiscal year, which goals were established by our board at its scheduled meeting in February 2007.

     At its scheduled meeting in February 2008, the board assessed the company’s performance during the 2007 fiscal year, including the following achievements:

	•		Total revenues of $94.4 million for the year ended December 31, 2007, representing 92% growth as compared to the prior year;
	•		Net product sales of $79.4 million for the year ended December 31, 2007, representing 73% growth as compared to the prior year;
	•		Net loss of $44.3 million for the year ended December 31, 2007, representing a reduction of $12.2 million as compared to the prior year;
	•		Year-end cash position, including cash, cash equivalents and short-term investments of $64.7 million as of December 31, 2007; and
	•		Execution of co-promotion agreements for Naprelan® (naproxen sodium) Controlled Release Tablets in June 2007 and Fleet® Phospho-soda® EZ-Prep™ in August 2007.

The board also considered the company’s achievement of 116% year-over-year growth in Zegerid^® brand total prescriptions, while total prescriptions for the other branded proton pump inhibitor, or PPI, products as a group declined during the same

period, and the company’s execution of license and distribution agreements with GlaxoSmithKline in November 2007 relating to the company’s immediate-release PPI technology.

     Following this assessment, the board determined that the overall level of attainment of the 2007 corporate goals was 76%. The corporate goals included the achievement of performance targets related to our year-end financial results (including total revenues, product sales, net loss and year-end cash) and the addition of a marketed product through a co-promotion or acquisition transaction.

     As a result of the board’s determination, for the 2007 fiscal year, Mr. Proehl received a bonus of $190,000, which was equal to 38% of Mr. Proehl’s base salary, and each of the other Named Executive Officers received bonuses equal to approximately 27% of their respective base salaries. The specific amounts of the cash bonuses awarded to our Named Executive Officers for the 2007 fiscal year are reflected in the Summary Compensation Table. Consistent with the overall compensation philosophy, the total cash compensation for our executive officers, including the cash bonuses and the base salary levels described above, was at less than the 50th percentile of the total cash compensation paid to executives holding comparable positions within our peer companies, due to the fact that our executive officers received less than 100% of their target cash bonuses based on company performance consistent with the pay for performance nature of the bonus plan.

          Long-Term Incentives

               Stock Option Awards

     Our long-term incentives are primarily in the form of stock option awards, and the company’s executive officers, along with all of the company’s other employees, are eligible to participate in the company’s award of stock options. As discussed above, the objective of these awards is to further enhance our executive officers’ long-term incentive to increase stockholder value and the company’s stock price. We believe that stock option based compensation achieves this objective by directly linking the economic benefit to recipients of such awards with our stock’s performance. We also believe that stock option based compensation encourages employee retention because the awards are designed to vest over time, generally over four years.

     The compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) have authority to grant stock option awards to our executive officers. In the case of stock option awards, which are generally made in connection with the compensation committee’s annual review of company performance and executive officer performance (and the independent members of our board of directors annual review of Mr. Proehl’s performance) conducted in the first quarter of each year, the number of stock options granted to each executive officer is determined based upon input from our third party consulting and survey firms and competitive compensation information for our peer companies. As described above, when reviewing the third party survey data, the compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) considered whether total equity compensation for our executive officers was generally at the 75^th percentile of the total equity compensation paid to executives holding comparable positions within our peer companies. The targeting of equity compensation at the 75^th percentile level, as compared to cash compensation at the 50^th percentile level, reflects the compensation committee’s strong belief in a pay for performance culture and alignment of executive compensation to long-term increases in stockholder value. The compensation committee (and the independent members of our board of directors, with respect to Mr. Proehl) also consider each executive officer’s individual performance (including the executive’s accomplishments and effectiveness) when determining the specific number of options to be awarded. In addition, the compensation committee takes into account the number of outstanding option grants held by each executive officer, and their vested status, in determining the specific number of options to be awarded.

     The exercise price of options granted under our stock plans has always been 100% of the fair market value of the underlying stock at the time of grant, and the company does not have a policy of granting equity-based awards at other than the fair market value. For options granted on or after January 1, 2007, the fair market value of our common stock is determined by reference to the closing price of our common stock on the Nasdaq Global Market on the date of grant. The majority of the outstanding options held by our executive officers vest over a four-year period and are exercisable over a ten-year period following the date of grant unless employment terminates prior to such date.

     Our general policy is to grant options on fixed dates during open trading windows and on dates determined in advance in the prior year, although there may be occasions when grants are made on other dates. All required approvals are obtained in advance of or on the actual grant date. We do not time the granting of our options to take advantage of any favorable or

unfavorable news released by the company.

     During the 2007 fiscal year, Mr. Proehl was granted an option in February 2007 to purchase 225,000 shares of our common stock, in connection with the annual review of corporate performance during 2006 and Mr. Proehl’s individual performance during 2006 and also considering the level of his then current ownership of shares of our common stock. Each of the other Named Executive Officers was granted an option in February 2007 to purchase a number of shares of our common stock, ranging from 70,000 to 80,000 shares, in connection with the annual review of corporate and individual performance during 2006. Stock option awards granted during the 2007 fiscal year to Mr. Proehl and the other Named Executive Officers are reflected in the table captioned “Grants of Plan-Based Awards,” and outstanding stock option awards as of December 31, 2007 are reflected in the table captioned “Outstanding Equity Awards at Fiscal Year-End.” Consistent with the overall compensation philosophy, the total equity compensation for our executive officers was at the 75th percentile of the total equity compensation paid to executives holding comparable positions within our peer companies.

     Commencing with the options granted in the 2008 fiscal year, which will be reflected in more detail in the proxy statement to be filed in connection with the annual stockholders’ meeting in 2009, the compensation committee determined to structure a significant portion of the options granted to our executive officers with performance-based vesting. These options will vest only upon attainment of specified financial performance targets. The compensation committee believes that performance-based equity awards strongly align executive compensation with company performance.

     Options granted to any of our employees under our amended and restated 2004 equity incentive award plan, as well as currently outstanding unvested options granted under the 1998 stock option plan (our predecessor stock option plan), become fully vested and exercisable in the event of a change in control where the acquirer does not assume the options. In the event of a change in control where the acquirer does assume the options, such options will be subject to accelerated vesting prior to the change in control such that 50% of the unvested shares subject to the options will become vested and exercisable. In addition, assumed options will automatically become fully vested and exercisable if the holder of such options is terminated by the acquirer without cause or the holder terminates employment for good reason within 12 months after the change in control. Moreover, our executive officers are entitled to further acceleration of vesting in certain termination events under the terms of their employment agreements, as described below under the heading “Employment Agreements.”

          Perquisites

     We do not provide any perquisites for our executive officers.

          Other Benefits

     We provide benefits such as medical, dental and life insurance and disability coverage for all of our employees, including our executive officers. In addition, we have established an amended and restated employee stock purchase plan and a section 401(k) savings/retirement plan available to all eligible employees, including our executive officers. We also provide personal paid time off and other paid holidays to all employees, including the executive officers, which are similar to those provided at comparable companies.

          Tax Considerations

     As part of its compensation program, the company aims to compensate the company’s executive officers in a manner that is tax effective for the company. In practice, the equity-based compensation elements of the compensation delivered by the company is not subject to the deduction limitation imposed under Section 162(m) of the Internal Revenue Code, or the Code, as amended. Section 162(m) of the Code generally limits the tax deductions a public corporation may take for compensation paid to its chief executive officer and three other most highly compensated executive officers, other than its chief financial officer, the Named Executive Officers, to $1.0 million per executive per year. Our stockholders have previously approved our stock award plans, the 1998 stock option plan and the amended and restated 2004 equity incentive award plan, qualifying options and stock appreciation rights under these plans as performance-based compensation intended to be exempt from the Section 162(m) limits. Other awards under these plans also may be granted with the intention of being performance-based compensation in the discretion of the compensation committee.

     Employment Agreements

     In order to specify our expectations with regard to our executive officers’ duties and responsibilities and to provide greater certainty with regard to the amounts payable to our executive officers in connection with certain terminations or change in control events, our compensation committee has approved and we have entered into employment agreements with each of our executive officers. Except as provided below, all of the employment agreements with our executive officers contain substantially similar terms. The payment and severance terms in the employment agreements were established based on market factors when the agreements were originally entered into, and they are reviewed annually by our compensation committee for continued appropriateness. The potential availability of severance benefits under these agreements did not impact the analysis of the other elements of compensation for the 2007 fiscal year because such benefits serve different purposes than the other elements of compensation. The compensation committee believes these agreements are appropriate to attract and retain individuals at the executive officer level and to properly balance the interests of executives and stockholders, as executives may be asked to consider actions which create stockholder value, but may also result in loss of an executive’s position. The level of payments under the agreements are designed to be fair and reasonable considering the time it would take an executive to find a position of comparable scope.

     Pursuant to the employment agreements, each executive is required to devote substantially all of his or her time and attention to our business and affairs. The initial base salaries of the executives are set forth in their employment agreements. The employment agreements do not provide for automatic annual increases in salary, but each employment agreement provides for annual salary reviews by the compensation committee. Each of the executives is eligible to participate in any management incentive compensation plan adopted by us or such other bonus plan as our board of directors or compensation committee may approve. The award of any bonus compensation is to be determined by the compensation committee or pursuant to a plan approved by the board of directors or compensation committee. Each of the executives is an at-will employee.

          Severance Benefits and Change in Control Arrangements

     The employment agreements provide each executive with certain severance benefits in the event his or her employment is terminated as a result of his or her death or permanent disability. Specifically, in the event of such a termination, the executive or his or her estate, as applicable, shall receive a lump sum payment of 12 months of salary and an amount equal to the average of the executive’s bonuses for the three years prior to the date of termination (for all executives other than Mr. Proehl, prorated for the period of time served by the executive during the year of termination), plus 12 months healthcare and life insurance benefits continuation at our expense. In addition, that portion of the executive’s stock awards, and any unvested shares issued upon the exercise of such stock awards, which would have vested if the executive had remained employed for an additional 12 months will immediately vest on the date of termination.

     The employment agreements also provide each executive with certain severance benefits in the event his or her employment is terminated by us other than for cause or if the executive resigns with good reason. Specifically, in the event of such a termination or resignation, all executives other than Mr. Proehl will receive a lump sum payment of 12 months of salary and an amount equal to the average of the executive’s bonuses for the three years prior to the date of termination (prorated for the period of time served by the executive during the year of termination), 12 months healthcare and life insurance benefits continuation at our expense, plus $15,000 towards outplacement services. If such termination or resignation occurs more than three months prior to or more than 12 months following a change of control, that portion of the executive’s stock awards, and any unvested shares issued upon the exercise of such stock awards, which would have vested if the executive had remained employed for an additional 12 months, will immediately vest on the date of termination.

     With respect to Mr. Proehl, in the event his employment is terminated by us other than for cause or if he resigns with good reason, Mr. Proehl will be entitled to receive a lump sum payment of 12 months of salary and an amount equal to the average of his bonuses for the three years prior to the date of termination, 12 months of healthcare and life insurance benefits continuation at our expense, plus $15,000 towards outplacement services; provided, however, that if such termination or resignation occurs within three months prior to or within 12 months following a change of control, Mr. Proehl will be entitled to receive 18 months of salary and an amount equal to the average of his bonuses for the three years prior to the date of termination, 18 months of healthcare and life insurance benefits continuation at our expense, plus $15,000 towards outplacement services. If such termination or resignation occurs more than three months prior to or more than 12 months following a change of control, that portion of Mr. Proehl’s stock awards, and any unvested shares issued upon the exercise of

such stock awards, which would have vested if Mr. Proehl had remained employed for an additional 12 months, will immediately vest on the date of termination.

     In addition, with respect to all executives (including Mr. Proehl), if such termination occurs within three months prior to or within 12 months following a change in control, all of the executive’s remaining unvested stock awards, and any unvested shares issued upon the exercise of such stock awards, will immediately vest on the date of termination.

     Apart from termination, the employment agreements also provide that, in connection with a change in control of the company, 50% of the executive’s unvested stock awards, and any unvested shares issued upon the exercise of such stock awards, will immediately become vested. This accelerated vesting supersedes any less favorable accelerated vesting provided under our amended and restated 2004 equity incentive award plan and our 1998 stock option plan.

     Each of the employment agreements also provides that payments under each employment agreement may be delayed to the extent necessary to avoid adverse tax consequences for the affected executive officer under Section 409A of the Code.

     Additional information concerning the potential payments our executive officers may receive in the event of termination of their employment or a change in control of the company is provided in the table captioned “Potential Payments Upon Termination or Change in Control.”

Compensation Committee Report

     The compensation committee of the company’s board of directors has submitted the following report for inclusion in this Proxy Statement:

     The compensation committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Proxy Statement with management. Based on the committee’s review of and the discussions with management with respect to the Compensation Discussion and Analysis, the committee recommended to the board of directors that the Compensation Discussion and Analysis be included in this Proxy Statement and in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 for filing with the SEC.

     This report of the compensation committee shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.

     The foregoing report has been furnished by the compensation committee.

Michael E. Herman, Chairman
David F. Hale
Kent Snyder

SUMMARY COMPENSATION TABLE

     The table below summarizes the total compensation paid or earned by each of our Named Executive Officers for the fiscal year ended December 31, 2007.

														Option				All Other
						Salary				Bonus				Awards				Compensation				Total
Name and Principal Position		Year				($)				($)(1)				($)(2)				($)(3)				($)
Gerald T. Proehl, President and Chief			2007			$	489,500			$	190,000			$	566,946			$	2,031			$	1,248,477
Executive Officer			2006				434,167				222,870				744,199				—				1,401,236
Debra P. Crawford, Senior Vice President, Chief			2007				289,753				77,571				239,523				3,375				610,222
Financial Officer, Treasurer and Secretary			2006				278,393				100,105				356,723				—				735,221
Julie A. DeMeules, Senior Vice President,			2007				233,273				63,840				237,866				3,375				538,354
Human Resources			2006				213,362				77,112				313,418				—				603,892
William C. Denby, III, Senior Vice President,			2007				281,408				75,220				233,440				2,113				592,181
Commercial Operations			2006				273,429				98,013				355,540				—				726,982
Warren E. Hall, Senior Vice President,			2007				264,914				70,811				224,921				2,205				562,851
Manufacturing and Product Development			2006				256,795				92,267				345,447				—				694,509

GRANTS OF PLAN-BASED AWARDS

     The table below provides information about stock option awards granted to our Named Executive Officers during the fiscal year ended December 31, 2007.

						Option Awards:
						Number of				Exercise or
						Shares of				Base Price				Grant Date
						Stock or				of Option				Fair
		Grant				Units				Awards				Value
Name		Date				(#)(1)				($/Sh)(2)				($)(3)
Gerald T. Proehl			03/12/07				225,000			$	6.90			$	929,025
Debra P. Crawford			03/12/07				80,000				6.90				330,320
Julie A. DeMeules			03/12/07				80,000				6.90				330,320
William C. Denby, III			03/12/07				70,000				6.90				289,030
Warren E. Hall			03/12/07				70,000				6.90				289,030

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

     The table below provides information about outstanding equity awards for each of our Named Executive Officers as of December 31, 2007.

		Option Awards
										Equity
										Incentive
										Plan Awards:
		Number of				Number of				Number of
		Securities				Securities				Securities
		Underlying				Underlying				Underlying
		Unexercised				Unexercised				Unexercised				Option
		Options				Options				Unearned				Exercise				Option
		(#)				(#)				Options				Price				Expiration
Name		Exercisable				Unexercisable				(#)				($)				Date(8)
Gerald T. Proehl			42,187	(1)			182,813				—			$	6.900				03/12/17
			45,833	(1)			54,167				—				6.790				02/09/16
			40,000	(2)			—				—				6.380				09/21/15
			70,833	(1)			29,167				—				7.150				02/15/15
			113,287	(3)			—				—				3.500				12/23/13
			460,691	(4)			—				—				0.875				05/22/13
			85,714	(3)			—				—				1.050				01/11/12
			38,571	(5)			—				—				1.050				12/18/11
			70,000	(6)			—				—				0.700				03/30/11
Debra P. Crawford			15,000	(1)			65,000				—				6.900				03/12/17
			22,916	(1)			27,084				—				6.790				02/09/16
			25,000	(2)			—				—				6.380				09/21/15
			46,041	(1)			18,959				—				7.150				02/15/15
			56,643	(3)			—				—				3.500				12/23/13
			132,138	(4)			—				—				0.875				05/22/13
			12,857	(5)			—				—				1.050				12/18/11
Julie A. DeMeules			15,000	(1)			65,000				—				6.900				03/12/17
			34,374	(1)			40,626				—				6.790				02/09/16
			25,000	(2)			—				—				6.380				09/21/15
			46,041	(1)			18,959				—				7.150				02/15/15
			57,142	(7)			—				—				5.250				01/30/14
William C. Denby, III			13,125	(1)			56,875				—				6.900				03/12/17
			20,625	(1)			24,375				—				6.790				02/09/16
			25,000	(2)			—				—				6.380				09/21/15
			46,041	(1)			18,959				—				7.150				02/15/15
			56,643	(3)			—				—				3.500				12/23/13
			86,946	(4)			—				—				0.875				05/22/13
Warren E. Hall			13,125	(1)			56,875				—				6.900				03/12/17
			22,916	(1)			27,084				—				6.790				02/09/16
			25,000	(2)			—				—				6.380				09/21/15
			46,041	(1)			18,959				—				7.150				02/15/15
			56,643	(3)			—				—				3.500				12/23/13
			107,741	(4)			—				—				0.875				05/22/13

OPTION EXERCISES

     The table below provides information about stock option awards exercised by our Named Executive Officers during the fiscal year ended December 31, 2007.

		Option Awards
		Number of Shares				Value Realized
		Acquired on Exercise				on Exercise
Name		(#)				($)(1)
Gerald T. Proehl			—			$	—
Debra P. Crawford			—				—
Julie A. DeMeules			—				—
William C. Denby, III			25,000				37,250
Warren E. Hall			—				—

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

     The table below reflects the amount of compensation that each of our Named Executive Officers would be entitled to receive under his or her existing employment agreement with our company upon termination of such executive’s employment in certain circumstances. The amounts shown assume that such termination was effective as of December 31, 2007 (with the amount of severance based on the executive’s base salary as of such date), and thus include amounts earned through such time and are only estimates of the amounts that would be paid out to such executives upon termination of their employment. The actual amounts to be paid out can only be determined at the time of such executive’s separation from our company. Please see the section above entitled “Compensation Discussion and Analysis – Employment Agreements” for further discussion.

				Termination				Termination
				w/o Cause or				w/o Cause or
				for Good Reason				for Good Reason
				(apart from				(in connection				Death
				change in				with change				or				Change in
Name		Benefit		control)				in control)				Disability				Control(3)
Gerald T. Proehl		Severance		$	500,000			$	750,000			$	500,000			$	—
		Cash Bonus			168,207				168,207				168,207				—
		Accelerated Option Vesting(1)			76,450				76,450				76,450				38,225
		Healthcare and Life Insurance Benefits(2)			17,642				26,463				17,642				—
		Outplacement Services			15,000				15,000				—				—
		Total Value:			777,299				1,036,120				762,299				38,225
Debra P. Crawford		Severance			291,622				291,622				291,622				—
		Cash Bonus			76,774				76,774				76,774				—
		Accelerated Option Vesting(1)			20,648				20,648				20,648				10,324
		Healthcare and Life Insurance Benefits(2)			17,023				17,023				17,023				—
		Outplacement Services			15,000				15,000				—				—
		Total Value:			421,067				421,067				406,067				10,324
Julie A. DeMeules		Severance			240,000				240,000				240,000				—
		Cash Bonus			53,444				53,444				53,444				—
		Accelerated Option Vesting(1)			—				—				—				—
		Healthcare and Life Insurance Benefits(2)			17,618				17,618				17,618				—
		Outplacement Services			15,000				15,000				—				—
		Total Value:			326,062				326,062				311,062				—
William C. Denby, III		Severance			282,781				282,781				282,781				—
		Cash Bonus			75,999				75,999				75,999				—
		Accelerated Option Vesting(1)			18,051				18,051				18,051				9,026
		Healthcare and Life Insurance Benefits(2)			17,642				17,642				17,642				—
		Outplacement Services			15,000				15,000				—				—
		Total Value:			409,473				409,473				394,473				9,026
Warren E. Hall		Severance			266,206				266,206				266,206				—
		Cash Bonus			70,956				70,956				70,956				—
		Accelerated Option Vesting(1)			16,836				16,836				16,836				8,418
		Healthcare and Life Insurance Benefits(2)			17,642				17,642				17,642				—
		Outplacement Services			15,000				15,000				—				—
		Total Value:			386,640				386,640				371,640				8,418

Equity Compensation Plan Information

     The following table sets forth information regarding all of our equity compensation plans as of December 31, 2007.

Number of Securities

Number of Securities

Weighted-Average

Remaining Available for

to

Exercise Price of

Future Issuance Under

be Issued upon

Outstanding

Equity Compensation

Exercise

Options,

Plans (Excluding

of Outstanding Options,

Warrants and

Securities Reflected in

Plan Category

Warrants and Rights

Rights

Column (a))

(a)

(b)

(c)

Equity compensation plans approved by security holders

9,948,464

$

5.57

2,370,355

(1)

Equity compensation plans not approved by security holders

—

—

—

Total

9,948,464

$

5.57

2,370,355

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

     Pursuant to our Audit Committee Charter, the audit committee of our board of directors is responsible for reviewing and approving all transactions with related parties.  We have not adopted written procedures for review of, or standards for approval of, these transactions, but instead the audit committee of our board of directors intends to review such transactions on a case by case basis.  In addition, the compensation committee of our board of directors and/or our board of directors reviews all compensation-related policies involving our directors and executive officers. 

     During 2007, we believe that there has not been any transaction or series of similar transactions to which we were or are to be a party in which the amount involved exceeds $120,000 and in which any director, executive officer or holder of more than 5% of our common stock, or members of any such person’s immediate family, had or will have a direct or indirect material interest, other than compensation described under the headings “Proposal 1 Election of Directors – Compensation of Directors” and “Executive Compensation and Other Information.” We intend that any such future transactions will be approved by the audit committee of our board of directors and will be on terms no less favorable to our company than could be obtained from unaffiliated third parties.

PROPOSAL 2

RATIFICATION OF APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     Our board of directors has appointed Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2008 and has directed that management submit the appointment of our independent registered public accounting firm to the stockholders for ratification at the Annual Meeting. Ernst & Young LLP has audited our financial statements since 1998 and through the year ended December 31, 2007. Representatives of Ernst & Young LLP will be present at the Annual Meeting, will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

     Stockholders are not required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm. However, we are submitting the appointment of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate practice. If you fail to ratify the appointment, our board of directors and the audit committee will reconsider whether or not to retain Ernst & Young LLP. Even if the appointment is ratified, our board of directors and the audit committee in their discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of our company and our stockholders.

     The affirmative vote of the holders of a majority of the shares of our common stock represented and voting at the Annual Meeting will be required to ratify the appointment of Ernst & Young LLP.

Audit and All Other Fees

     The aggregate fees billed to our company by Ernst & Young LLP, our independent registered public accounting firm, for the indicated services were as follows:

		2007				2006
Audit Fees(1)		$	618,667			$	607,752
Audit Related Fees(2)			2,090				2,500
Tax Fees(3)			—				—
All Other Fees(4)			—				—

     The audit committee has considered whether the provision of non-audit services is compatible with maintaining the independence of Ernst & Young LLP, and has concluded that the provision of such services is compatible with maintaining the independence of our auditors.

Audit Committee Policy Regarding Pre-Approval of Audit and Permissible Non-Audit Services of Our Independent Registered Public Accounting Firm

     Our audit committee has established a policy that all audit and permissible non-audit services provided by our independent registered public accounting firm will be pre-approved by the audit committee. These services may include audit services, audit-related services, tax services and other services. The audit committee considers whether the provision of each non-audit service is compatible with maintaining the independence of our auditors. Pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. Our independent registered public accounting firm and management are required to periodically report to the audit committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date.

     Our board of directors recommends a vote “FOR” the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2008.

COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

     Under Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), directors, officers and beneficial owners of ten percent or more of our common stock are required to file with the Securities and Exchange Commission on a timely basis initial reports of beneficial ownership and reports of changes regarding their beneficial ownership of our common stock. Officers, directors and 10% beneficial owners are required by Securities and Exchange Commission regulations to furnish us with copies of all Section 16(a) forms that they file.

     Based solely on our review of the copies of such forms received and the written representations from certain reporting persons, we have determined that no officer, director or 10% beneficial owner known to us was delinquent with respect to their reporting obligations as set forth in Section 16(a) of the Exchange Act during the fiscal year ended December 31, 2007.

STOCKHOLDER PROPOSALS

     Proposals of stockholders intended to be presented at our Annual Meeting of Stockholders to be held in 2009 must be received by us no later than December 26, 2008, which is 120 days prior to the first anniversary of the mailing date of this Proxy Statement, in order to be included in our proxy statement and form of proxy relating to that meeting. These proposals must comply with the requirements as to form and substance established by the Securities and Exchange Commission for such proposals in order to be included in the proxy statement. Under our Amended and Restated Bylaws, a stockholder who wishes to make a proposal at the 2009 Annual Meeting without including the proposal in our proxy statement and form of proxy relating to that meeting must notify us no earlier than February 12, 2009 and no later than March 14, 2009 unless the date of the 2009 annual meeting of stockholders is more than 30 days before or more than 60 days after the one-year anniversary of the 2008 annual meeting. If the stockholder fails to give notice by this date, then the persons named as proxies in the proxies solicited by the board of directors for the 2009 Annual Meeting may exercise discretionary voting power regarding any such proposal.

ANNUAL REPORT

     Our annual report for the fiscal year ended December 31, 2007 will be mailed to stockholders of record on or about April 25, 2008. Our annual report does not constitute, and should not be considered, a part of this proxy solicitation material.

     Any person who was a beneficial owner of our common stock on the Record Date may request a copy of our annual report, and it will be furnished without charge upon receipt of a written request identifying the person so requesting a report as a stockholder of our company at such date. Requests should be directed to Santarus, Inc., 3721 Valley Centre Drive, Suite 400, San Diego, California 92130, Attention: Investor Relations.

OTHER BUSINESS

     Our board of directors does not know of any matter to be presented at our Annual Meeting which is not listed on the Notice of Annual Meeting of Stockholders and discussed above. If other matters should properly come before the meeting, however, the persons named in the accompanying proxy card will vote all proxies in accordance with their best judgment.

     All stockholders are urged to complete, sign, date and return the accompanying proxy card in the enclosed envelope.

By Order of the Board of Directors,

Gerald T. Proehl
President, Chief Executive Officer and Director

Dated: April 25, 2008

1.		To elect two directors for a three-year term to expire at the 2011 Annual Meeting of Stockholders. The present Board of Directors of the Company has nominated and recommends for election as director the following persons:

INSTRUCTION:	To withhold authority to vote for any individual nominee(s), mark “FOR ALL EXCEPT” and fill in the circle next to each nominee you wish to withhold, as shown here: l

     

---

THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS GIVEN, THIS PROXY WILL BE VOTED FOR THE NOMINEES FOR DIRECTOR LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2.

In their discretion, the proxy holders are authorized to vote upon such other business as may properly come before the annual meeting or any adjournment or postponement thereof.

All other proxies heretofore given by the undersigned to vote shares of stock of the Company, which the undersigned would be entitled to vote if personally present at the annual meeting or any adjournment or postponement thereof, are hereby expressly revoked.

PLEASE MARK, SIGN, DATE AND PROMPTLY RETURN THE PROXY CARD USING THE ENCLOSED ENVELOPE. IF YOUR ADDRESS IS INCORRECTLY SHOWN, PLEASE PRINT CHANGES.